Survey of the Effect of Omega-3 in the Prevention of Preeclampsia in Pregnant Women Suffering Hyperlipidemia

The aim of this study is survey of the relationship between omega-3 administrations in pregnant women suffering hyperlipidemia with prevention of preeclampsia.

A clinical trial with a control group, with intervention and control groups, double-blind, randomized block, on 72 patients. A checklist was used for randomization.

This clinical trial study will be performed on pregnant women with hyperlipidemia referred to the infertility treatment center of Besat Hospital of Kurdistan University of Medical Sciences in Sanandaj city, Kurdistan Province, Iran. Pregnant women with hyperlipidemia are randomly divided into two groups and treated with omega-3. Finally, patients are evaluated for preeclampsia during childbirth.

Entry conditions ؛Pregnant women suffering hyperlipidemia with triglyceride levels above 150 milligrams per deciliter; no entry conditions: pregnant women with metabolic diseases, pregnant women with the age of less than 20 years and over the age of 40 years, pregnant women with a history of preeclampsia in a previous pregnancy or in a first-degree relative, pregnant women with a history of having twins, pregnant women with a body mass index equal to or greater than 29, pregnant women with kidney disease, high blood pressure, diabetes and hyperthyroidism, pregnant women that use of aspirin, calcium, anticoagulants and insulin, pregnant women that do not have history of omega-3 allergies.

Intervention group A: 36 pregnant women aged 20 to 40 years with hypertriglyceridemia who received omega-3 daily in the form of one gram capsule. Intervention group B: 36 pregnant women aged 20 to 40 years with hypertriglyceridemia who received the placebo daily in the form of one 100 mg gelatin capsule.

Preeclampsia

Randomization of patients will do by randomization method of 4 blocks (AA, BB-AB, AB-BA, BA-AA, BB). So exactly the same numbers of participants enter the intervention and control groups in the consecutive but equal intervals. Therefore, two groups are considered. Patients in intervention group A, that received omega-3 and placebo group B, that received placebo. Intervention group A receives omega-3 in the form of one gram tablet containing Eicosapentaenoic acid and Docosahexaenoic acid daily until the end of pregnancy. The placebo group receives the placebo daily in the form of gelatin capsules until the end of pregnancy. Patients will be referred for blood pressure measurement during pregnancy and will be evaluated for triglyceride measurements. The necessary information for the study is collected using a checklist and finally the incidence of eclampsia between the intervention and placebo groups will be analyzed and compared.

The control group receives a placebo, which is in the form of gelatin capsules and will be used daily until the end of pregnancy.

Part of the data, such as information about the main outcome or the like that has been analyzed, can be shared as an article published in the journal.

"Start of access period from 2022"

The data will be available to researchers working in academic and scientific institutions, people working in industry.

The use of data for scientific applications and treatment of patients can be used by mentioning the name and permission of researchers.

Kurdistan Province, Sanandaj, Abidar Street, Besat Hospital, Infertility Treatment Center, Email: shahgheibi@yahoo.com, Phone Number: 09181710443, Name and Family: Sholeh Shah Gheibi

Send the request to the e-mail of the responsible author, mentioning the reason for the request, if it is appropriate, will be sent after a week to a month.